×
About 495 results

ALLMedicine™ Acquired Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  151 results

Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA Va...
https://doi.org/10.1055/s-0042-1744301
Seminars in Thrombosis and Hemostasis; Tso ACY, Ong KH et. al.

Jun 28th, 2022 - Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA Vaccine?|2022|Tso ACY,Ong KH,Sum CLL,Fan BE,Chan GYL,|

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Repo...
https://doi.org/10.1093/labmed/lmac016
Laboratory Medicine; Hammami E, Lamarque M et. al.

Apr 29th, 2022 - Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy that is deadly if not treated promptly. The treatment of choice in patients presenting with TTP is plasma exchanges. However, immunosuppressive therapy and caplacizumab have...

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
https://clinicaltrials.gov/ct2/show/NCT04074187

Apr 25th, 2022 - Study duration per participant is approximately 2 months up to approximately 6 months in case of treatment extension and recurrence during the study drug treatment period.

Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006270
Blood Advances;

Apr 12th, 2022 - Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092.|2022||therapeutic use,drug therapy,

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
https://clinicaltrials.gov/ct2/show/NCT02878603

Mar 28th, 2022 - The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

see more →

Drugs  3 results see all →

Clinicaltrials.gov  7 results

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
https://clinicaltrials.gov/ct2/show/NCT04074187

Apr 25th, 2022 - Study duration per participant is approximately 2 months up to approximately 6 months in case of treatment extension and recurrence during the study drug treatment period.

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
https://clinicaltrials.gov/ct2/show/NCT02878603

Mar 28th, 2022 - The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
https://clinicaltrials.gov/ct2/show/NCT05262881

Mar 2nd, 2022 - This study is a multicenter, retrospective, observational study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) treated with plasma exchange (PEX) in association with caplacizumab, and immunosuppression between Q4-2019 and 28 ...

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
https://clinicaltrials.gov/ct2/show/NCT03922308

Feb 21st, 2022 - The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
https://clinicaltrials.gov/ct2/show/NCT04021173

Jul 17th, 2019 - The study will consist of 3 periods: screening(up to 7 days), treatment and follow-up(up to 3 months). Subjects are assigned in a 1:1 ratio to Anfibatide or placebo during plasma exchange with the use of a computerized randomization schedule. The ...

see more →

News  37 results

Real-world outcomes of caplacizumab for iTTP comparable to clinical trial results
https://www.mdedge.com/hematology-oncology/article/238288/bleeding-disorders/real-world-outcomes-caplacizumab-ittp
Mark S. Lesney, PhD

Apr 7th, 2021 - Real-world data for caplacizumab outcomes matched those seen in randomized controlled trials (RCTs) for the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP), according to the results of a retrospective study. Data collected.

FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
https://www.onclive.com/view/fda-approvals-in-myeloma-and-attp-priority-review-designations-in-rcc-and-hnscc-and-more

Apr 2nd, 2021 - Today- FDA approvals in multiple myeloma and acquired thrombotic thrombocytopenic purpura, priority review designations in renal cell carcinoma and head and neck squamous cell carcinoma, an ODAC meeting scheduled in multiple myeloma, and a revi...

New Agents Abound in Benign Hematologic Disorders
https://www.onclive.com/view/new-agents-abound-in-benign-hematologic-disorders

Dec 20th, 2020 - Kleber Yotsumoto Fertrin, MD, PhD With the emergence of new agents in benign hematologic disorders and more in the pipeline, the outlook for patients with aplastic anemia, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TT...

Cost is the main hurdle to broad use of caplacizumab for TTP
https://www.mdedge.com/hematology-oncology/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
M. Alexander Otto

Dec 7th, 2020 - As hematologists debated the role of the anti–von Willebrand factor agent caplacizumab for acquired thrombotic thrombocytopenic purpura (TTP), an investigator on the phase 3 trial that led to its approval had a message. “If we take finances out” o.

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 16th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

see more →